AllSight
Companies · HROW · Pharmaceutical Preparations · Exec change · Sep 4, 2026

Harrow’s CFO takes over accounting role after Pollard departure, with no extra pay

CFO assumes accounting rolenew
CFO also designated principal accounting officer; no additional compensation
HARROW, INC. (HROW) — what happened, in plain English, and what it means versus what the market expected.

This is a management-responsibility change, not an operating update. The filing says Andrew Boll, already president and CFO, will also become principal accounting officer following Mr. Pollard’s departure. (Item 5.02) 〔0〕

The market read is neutral because there is no clean beat-or-miss benchmark here. The filing provides no earnings, guidance, financing, or strategic change to compare with expectations; it mainly signals continuity by consolidating accounting oversight under the existing CFO. Boll will receive no incremental compensation for the added designation. (Item 5.02) 〔1〕

The only open question is whether Pollard’s departure carries separate significance. This filing does not disclose the reason for the departure, transition details, or any impact on financial reporting, so the document alone supports a routine executive-change read rather than a broader fundamental conclusion.

Read the original 8-K on SEC EDGAR ↗
More from HARROW, INC. (HROW)
Aug 10, 2026Revenue nearly met estimates, but profitability sharply missed amid heavy investmentAug 6, 2026Adds TYRVAYA to its dry-eye franchise at modest upfront costAll HROW filings, decoded →
Related companies in Pharmaceutical Preparations
Latest across the market
FLOCFlowco acquisition adds Canadian rod lift but increases debt-funded execution riskCTRECareTrust acquisition adds 45 UK care homes, but SHOP payoff is years awayACNAccenture earnings beat as Q4 revenue clears guidance, but FY27 growth stays measuredROPRoper Technologies adds NTT DATA CEO to board, but brings no operating changeONON Semiconductor acquisition financing locks in $2.45B debt for Synaptics dealIIPRIIPR loan increase funds Alewife buildout, but locks in 14% debtBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.
Analysis by AllSight · Editorial standards & method · Contact